Summary
– A meta-analysis found inclisiran, given twice yearly, reduced LDL cholesterol about 49% more than placebo across trials.
– The FDA approved Lipfendra (enlicitide), the first oral PCSK9 inhibitor, which lowered LDL by roughly 56–59% in clinical studies.
– Updated AHA/ACC guidelines broaden who should be considered for statin therapy; one analysis estimates more than half of U.S. adults aged 30–79 are now eligible.
What the evidence shows
Inclisiran
A systematic review and meta-analysis of nine randomized trials reported that inclisiran produced a consistent and sizeable reduction in LDL cholesterol compared with placebo — about a 49% greater reduction overall. Inclisiran works by targeting the production of proteins involved in raising LDL levels and is dosed only twice a year, which may help people who struggle with daily pills. The FDA has expanded labeling to allow its use alone or together with statins, in addition to diet and exercise, for people with high cholesterol. Clinicians and researchers welcome the drug’s consistent LDL-lowering effect, but some experts note that outcome trials linking inclisiran’s LDL reductions to fewer heart attacks and strokes are still important to confirm clinical benefit.
Lipfendra (oral PCSK9 inhibitor)
On July 16 the FDA approved Lipfendra (enlicitide), the first oral PCSK9 inhibitor for adults with elevated LDL cholesterol. In two supporting trials, participants taking Lipfendra had mean LDL reductions of about 56% and 59% at 24 weeks. These trials were designed to measure LDL lowering; they did not directly measure whether Lipfendra reduces heart attacks or strokes. The FDA treats LDL reduction as an accepted surrogate for lower cardiovascular risk, based on extensive prior research linking lower LDL to lower heart disease risk.
Updated guidelines and who is affected
Earlier in the year the American Heart Association, American College of Cardiology and partner organizations released updated cholesterol screening and management guidance. Key changes include recommending earlier intervention, measuring lipoprotein(a) at least once to help identify inherited risk, using a newer risk calculator (PREVENT), and setting lower LDL targets for people at higher risk.
Analyses of these changes found major impacts on eligibility and risk classification:
– Roughly 56.6% of U.S. adults ages 30–79 (about 87.5 million people) now meet criteria for statin therapy under the new guidance; 21.5 million of those would not have met criteria under the 2018 recommendations.
– Large gaps remain in care: studies show more than three-quarters of high-risk adults without known cardiovascular disease and about one-third of people with established heart disease are not receiving recommended lipid-lowering therapy.
– The PREVENT risk calculator reclassified about 21.5% of adults into different risk categories; roughly two-thirds shifted to lower predicted risk while about one-third moved to higher predicted risk.
What this means for patients and clinicians
– More treatment options: Lipfendra provides an oral PCSK9 inhibitor option; inclisiran offers infrequent twice-yearly dosing. Both expand choices beyond daily statins and injectable PCSK9 monoclonal antibodies, potentially improving adherence and access.
– Surrogate vs outcomes: Both drugs demonstrate strong LDL lowering. For Lipfendra the FDA accepted LDL reductions as a validated surrogate; for inclisiran, clinicians are watching for outcome data tying LDL drops to reduced heart attacks and strokes.
– Personalized decisions: The updated guidelines emphasize individualized risk assessment, consideration of lipoprotein(a), and use of imaging or other risk enhancers when appropriate. Clinicians should weigh baseline risk, intolerance or inadequate response to statins, patient preferences, and cost/access issues when choosing therapy.
– Care gaps persist: Even with broader eligibility, many high-risk people are undertreated — closing that gap remains a priority.
Bottom line
New therapies and guideline changes are shifting the landscape of cholesterol management: more people are eligible for preventive treatment, and clinicians have new tools for patients who don’t reach LDL goals or who have trouble with daily medications. While LDL lowering is a well-established marker of cardiovascular risk, continued attention to outcome data, equitable access, and individualized care will guide optimal use of these advances.
